BIORA THERAPEUTICS INC (BIOR) Stock Analyst Earnings Estimates
NASDAQ:BIOR - Nasdaq - US74319F3055 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.2M 500.00% | 300K -75.00% | 4K -98.67% | 1M 24,890.00% | 2.553M 155.40% | 2.818M 10.38% | |
| EBITDA YoY % growth | -116.36M -13.48% | -60.89M 47.67% | -66.588M -9.36% | -66.912M -0.49% | -69.564M -3.96% | -79.356M -14.08% | |
| EBIT YoY % growth | -117.8M -9.48% | -61.8M 47.54% | -67.143M -8.65% | -63.569M 5.32% | -64.834M -1.99% | -71.601M -10.44% | |
| Operating Margin | -9,816.67% | -20,600.00% | -1,678,575.00% | -6,359.49% | -2,539.51% | -2,540.86% | |
| EPS YoY % growth | -557.50 64.98% | -51.40 90.78% | N/A -60.44% | -9.25 88.79% | -7.46 19.31% | -6.54 12.37% |
All data in USD
| Q4 / 24 | |
|---|---|
| EPS Q2Q % growth | -3.37 45.71% |
| Revenue Q2Q % growth | 102K |
| EBITDA Q2Q % growth | -18.462M -44.36% |
| EBIT Q2Q % growth | -14.044M -5.25% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -5.04 89.69% | -3.93 | -1.11 | -28.34% |
| Q2 2024 Q2Q % growth | 1.80 112.24% | -4.59 | 6.39 | 139.22% |
| Q1 2024 Q2Q % growth | -1.40 21.57% | -4.59 | 3.19 | 69.50% |
| Q4 2023 Q2Q % growth | -6.20 62.20% | -6.07 | -0.13 | -2.16% |
| Q3 2023 Q2Q % growth | -48.90 -552.00% | -9.44 | -39.46 | -418.28% |
| Q2 2023 Q2Q % growth | -14.70 -96.00% | -16.32 | 1.62 | 9.93% |
| Q1 2023 Q2Q % growth | 91.07% | -1.79 | % | |
| Q4 2022 Q2Q % growth | -16.40 88.29% | -14.74 | -1.66 | -11.27% |
| Q3 2022 Q2Q % growth | -7.50 93.48% | -19.13 | 11.63 | 60.78% |
| Q2 2022 Q2Q % growth | -7.50 95.38% | -30.60 | 23.10 | 75.49% |
| Q1 2022 Q2Q % growth | -20.00 85.71% | -31.88 | 11.88 | 37.25% |
| Q4 2021 Q2Q % growth | -140.00 63.40% | -40.80 | -99.20 | -243.14% |
| Q3 2021 Q2Q % growth | -115.00 54.46% | -113.90 | -1.10 | -0.97% |
| Q2 2021 Q2Q % growth | -162.50 89.36% | -205.70 | 43.20 | 21.00% |
| Q1 2021 Q2Q % growth | -140.00 | -207.06 | 67.06 | 32.39% |
| Q4 2020 Q2Q % growth | -382.50 | -209.61 | -172.89 | -82.48% |
| Q3 2020 Q2Q % growth | -252.50 | -182.58 | -69.92 | -38.30% |
| Q2 2020 Q2Q % growth | -1,527.50 | -211.65 | -1,315.85 | -621.71% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 32K | 214.2K | -182.2K | -85.06% |
| Q2 2024 Q2Q % growth | 318K 15,800.00% | 318K | % | |
| Q4 2023 Q2Q % growth | -100.00% | 510 | -510 | -100.00% |
| Q3 2023 Q2Q % growth | -100.00% | 510 | -510 | -100.00% |
| Q2 2023 Q2Q % growth | 2K -98.00% | 20.4K | -18.4K | -90.20% |
| Q1 2023 Q2Q % growth | -100.00% | % | ||
| Q4 2022 Q2Q % growth | 10K -97.73% | 56.1K | -46.1K | -82.17% |
| Q3 2022 Q2Q % growth | 80K -55.56% | 51K | 29K | 56.86% |
| Q2 2022 Q2Q % growth | 100K -78.26% | 100K | % | |
| Q1 2022 Q2Q % growth | 110K -35.29% | 110K | % | |
| Q4 2021 Q2Q % growth | 440K 300.00% | 255K | 185K | 72.55% |
| Q3 2021 Q2Q % growth | 180K 200.00% | 3.876M | -3.696M | -95.36% |
| Q2 2021 Q2Q % growth | 460K | 19.095M | -18.635M | -97.59% |
| Q1 2021 Q2Q % growth | 170K | 25.909M | -25.739M | -99.34% |
| Q4 2020 Q2Q % growth | 110K | 25.218M | -25.108M | -99.56% |
| Q3 2020 Q2Q % growth | 60K | 35.439M | -35.379M | -99.83% |
| Q2 2020 Q2Q % growth | 26.712M | -26.712M | -100.00% | |
| Q1 2020 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 10.81% | -695.18% | -2.43% | -924.29% |
| Revenue | -54.55% | N/A | -23.46% | -23.46% |